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Fig. 1. Schematic diagram of the cancer-selective killing of onco-
lytic Ads. Oncolytic Ads can specifically kill tumor cells by can-
cer cell-specific viral replication while sparing normal cells. 
Replicating viral agents in tumors may lead to improved efficacy 
over non-replicating Ads due to their inherent ability to multiply, 
lyse infected cancer cells, and spread to surrounding cells.
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An often overlooked issue in the field of adenovirus (Ad)- 
mediated cancer gene therapy is its limited capacity for effec-
tive systemic delivery. Although primary tumors can be treated 
effectively with intralesional injection of conventional Ad vec-
tors, systemic metastasis is difficult to cure. Systemic admin-
istration of conventional naked Ads leads to acute accumu-
lation of Ad particles in the liver, induction of neutralizing an-
tibody, short blood circulation half-life, non-specific bio-
distribution in undesired organs, and low selective accumu-
lation in the target disease site. Versatile strategies involving 
the modification of viral surfaces with polymers and nano-
materials have been designed for the purpose of maximizing 
Ad anti-tumor activity and specificity by systemic administra-
tion. Integration of viral and non-viral nanomaterials will sub-
stantially advance both fields, creating new concepts in gene 
therapeutics. This review focuses on current advances in the 
development of smart Ad hybrid nanocomplexes based on var-
ious design-based strategies for optimal Ad systemic adminis-
tration. [BMB reports 2010; 43(12): 781-788]
INTRODUCTION
Human cancer gene therapy has significantly progressed with 
the advent of adenovirus (Ad) vectors. Since 1993, numerous 
clinical trials involving over 392 clinical protocols have been 
conducted using Ad vector as a delivery vehicle (http://www. 
wiley.co.uk/genmed/clinical/). Ads have several technically 
useful attributes, including efficient nuclear entry mechanism, 
high gene transfer efficiency in both dividing and non-dividing 
cells, easy production of high-titer Ad stocks, low risk of inser-
tional mutagenesis, and induction of oncolysis by viral re-
plication. Gene delivery vehicles possessing these versatile 
molecular biological attributes are ideal for use in cancer 
virotherapy.
One emerging modality of cancer therapy is replication- 
competent oncolytic Ads that inherently multiply, lyse infected 
cancer cells, and spread to surrounding cancer cells, resulting 
in improved efficacy over non-replicating Ads (Fig. 1). Recent 
studies have reported the tumor-selective replication of onco-
lytic Ad, guaranteeing enhanced selective anti-tumor activity 
without killing normal healthy cells (1, 2). Moreover, combin-
ing the cell killing effect of tumor-selective replicating onco-
lytic Ad with gene therapy based on virus-mediated delivery 
and expression of transgenes will potentially have a significant 
impact on the efficacy of therapeutic tools for cancer treatment 
(3-5). Most importantly, the amplification and propagation of 
therapeutic genes using replicating viruses in infected neigh-
boring cells highlights the potential of replicating virus-based 
therapy for the treatment of heterogeneous human tumors. In 
addition, oncolytic Ads express therapeutic genes in a cancer 
cell-specific manner (6-8), resulting in minimal expression of 
unwanted genes in normal cells and high expression of ther-
apeutic genes in selected cancer cells. 
For virus-based gene therapy of metastasizing cancer to be 
successful, the virus must have easy access to the tumor cells, 
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which is made possible by a new delivery system charac-
terized by extended circulation time in plasma (9). Circulation 
of naked Ad in the blood causes acute viral accumulation and 
hepatocytosis in the liver, resulting in undesired gene ex-
pression and an inappropriate innate immune response. To 
avoid activating immune responses and hepatotoxicity, an ef-
fective Ad nanocomplex delivery system for systemic tumor 
therapy has been used for minimal hepatic distribution and 
high localization in tumor cells (10-12). This review describes 
the recent developments in the design of cancer-targeted Ad 
nanocomplexes to overcome limited systemic delivery effi-
ciency and inappropriate triggering of immune responses, 
thereby enhancing the efficacy and safety of anti-cancer ther-
apeutic strategies.
EFFORTS TO DEVELOP SYSTEMIC Ad DELIVERY
Thus far, Ad-mediated cancer gene therapy has been attempted 
only by intratumoral administration (13, 14) in order to accu-
mulate a high concentration of Ad in the local tumor site. 
However, systemic administration would make possible the 
treatment of disseminated metastatic tumors in addition to pri-
mary tumors, enabling Ads to access and infect widely dis-
tributed cancer cells. The most significant obstacle for Ad sys-
temic administration is the induction of strong innate immune 
responses. Kupffer cells (KCs) in the liver and spleen cells im-
mediately uptake naked Ad, resulting in immune cell secretion 
of inflammatory cytokines such as interleukin (IL)-6 and IL-12, 
which cause local acute inflammation (15). The expression of 
these pro-inflammatory cytokines combined with the seques-
tration of intravenously administered Ad by KCs in the liver in-
duces hepatotoxicity. Outside of the liver, Ad transduction of 
cells in other organs also attributes to potential Ad side effects. 
Another hurdle for Ad systemic administration is the gen-
eration of Ad-specific neutralizing antibody, which masks viral 
capsid proteins and inhibits Ad infection. This neutralizing an-
tibody may reduce the level of therapeutic gene expression as 
well as the efficacy of repeated Ad administration. 
Although attempts to resolve these difficulties have been 
made using various molecular biology techniques such as ge-
netic manipulation of Ad capsid protein and substitution of Ad 
serotypes, very little in vivo progress has been made. Therefore, 
to overcome these hurdles, other strategies involving the 
chemical and physical modification of Ad vectors have been 
employed with the goals of attaining preferential tumor target-
ing, prolonged systemic circulation, minimal side effects, phar-
macological analysis, and feasible but optimized clinical po-
tential. Advances in Ad modification now involve smart nano-
complexes, which possess advantages related to specificity, 
sensitivity, and charge reversibility.
Ad NANOCOMPLEXES FOR SYSTEMIC DELIVERY 
The need for systemic administration of Ad therapeutics has 
been recognized with recent advances in nanotechnology and 
pharmaceutics, making it possible to engineer numerous 
chemical modifications of the Ad surface using polymeric ma-
terials (16, 17). Originally, systemic and targeted delivery of 
Ads was performed by a versatile polymeric design and depot 
system, or by self-assembly in the pharmaceutical field. The 
need to unite virus and systemic delivery carriers has been rec-
ognized for systemic virotherapy (16, 18, 19). Customized 
strategies can be exploited to direct carriers to a specific dis-
ease site, prolong systemic circulation, and modulate the cel-
lular microenvironment. These virus nanocomplex-based ther-
apy strategies utilize passive accumulation based on enhanced 
permeation and retention (EPR) effects at the tumor site, active 
targeting with coordination of targeting moieties, and site-spe-
cific activatable targeting. Additionally, integral research stud-
ies have shown synergistic effects, taking advantage of both 
non-viral and viral gene carriers for systemic delivery. 
Polymer complexes with polyethylene glycol (PEG) and 
poly-N-(2-hydroxypropyl) methacrylamide (pHPMA)
In general, chemical modification of Ad is carried out by cross- 
linking of poly-N-(2-hydroxypropyl) methacrylamide (pHPMA) 
and PEGylation via amine functional groups on the Ad surface. 
The exterior of the Ad surface has approximately 1,800 ex-
posed lysine molecules located on the hexon, penton, and fi-
ber proteins (20). PEGylation and pHPMA conjugation of Ad is 
easily applied via amine-mediated simple chemistry. O’Rior-
dan et al. performed the first study on hybrid Ad complexes in 
1999, proving that PEGylation of amino groups on the Ad sur-
face reduces innate immune responses and shields the Ad sur-
face from neutralization by antibodies. These non-specific mo-
difications of the Ad surface with biopolymers reduce un-
desired interactions between plasma proteins in the blood 
stream. In addition, hybrid Ad complexes modified with bio-
compatible PEG and pHPMA help maintain Ad bioactivity in 
vivo protecting against deterioration by proteolysis, resulting in 
a prolonged half-life in blood (21). Moreover, PEG acts as a 
shield on the Ad surface, resulting in reduced hepatic uptake 
and adsorption of neutralizing antibody. Masking of molecular 
patterns on the Ad capsid by PEGylation was previously evi-
denced by a significant reduction in innate immune responses. 
After 6 hr of intravenous administration of PEGylated Ad, the 
plasma level of IL-6, which is the main indicator of an innate 
immune response against Ad, was reduced by 95% compared 
to that of naked Ad (22).
Previous studies have shown that the molecular weight of 
PEG determines the degree by which the innate immune re-
sponses against Ad are reduced (23). Yao et al. compared the 
biodistribution and reduction of immune responses against Ad 
after systemic administration of PEG [20K/45% modification 
ratio]-Ad and PEG [5K/90%]-Ad (24). Administration of Ad 
PEGylated with high molecular weight PEG, PEG [20K/45% 
modification ratio]-Ad, resulted in the desired biodistribution, 
including high Ad accumulation in tumor cells and plasma as 
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Fig. 2. Diagram of smart Ad nanocomplexes. 1. Specific affinity to
targeted tumor. 2. Physical adsorption via electrostatic interaction. 
3. Charge-convertible Ad in a weakly acidic extracellular tumor 
environment. 4. Ad complexes with positively charged bioredu-
cible polymer; recovery of Ad surface by reduction of disulfide 
backbone. 5. Cross-linking-mediated Ad nanocomplex prepared by 
electrospinning.
well as low distribution in the liver. The increased size of the 
Ad complex is attributed to the conjugation of Ad with longer 
chain PEG, resulting in avoidance of liver sinusoid fenestrae, 
which would lead to excretion of the Ad. Adequate shielding 
of the Ad capsid by longer chain PEG also enables the Ad to 
elude non-specific uptake by macrophages and KCs, which are 
responsible for innate immune responses (25-28). In addition, 
PEG can hide the Ad capsid and thus obscure recognition by 
the highly expressed Ad receptors coxsackievirus and ad-
enovirus receptor (CAR) and heparin sulphate, which are both 
expressed on KCs and hepatocytes (29, 30), resulting in sig-
nificantly augmented half-life in blood. This enhanced half-life 
of PEGylated Ad in the blood consequently promotes highly 
effective accumulation of Ad in tumor tissue via passive accu-
mulation based on the EPR effect (24, 26, 31). A previously 
published study quantitatively analyzed the biodistribution of 
PEGylated Ad using a bioluminescent reporter gene visualized 
in a metastatic model (24). The gene transfer efficacy of sys-
temically administered PEGylated Ad showed a high tu-
mor-to-liver ratio, proving that PEGylated Ad was highly lo-
calized in tumor cells via the EPR effect and resulted in en-
hanced anti-tumor treatment efficacy.
Another major polymer frequently used for Ad surface mod-
ification is pHPMA, which is randomly polymerized on the Ad 
surface (19). Biocompatible and hydrophilic HPMA copoly-
mers have been used for over 10 years as a drug delivery car-
rier and depot system, acting as a reservoir for drug storage 
and preventing protein absorption. Through extensive research, 
pHPMA was proven to have low toxicity and immunogenicity 
(19, 32). Affinity moieties on the pHPMA layer are made possi-
ble by reaction of amine-reactive 4-nitrophenyl ester (ONp) 
groups. The side chains of multivalent HPMA copolymers 
have also been utilized for conjugation with Ad surface amine 
groups, forming a stable polymeric layer on the Ad surface. In 
addition, pHPMA harbors numerous amine-reactive groups, 
which makes it possible to easily add hydrophilic PEG and af-
finity moieties for generation of a hydrophilic, stable, and 
dense polymeric layer on the Ad surface. This shell then pre-
vents the binding of neutralizing antibody while enabling tu-
mor-specific targeting.
SMART ENVELOPES ON THE Ad SURFACE
Specificity 
PEGylated Ads have prolonged half-lives in the plasma circu-
lation, enhanced EPR effects, and reduced absorption of neu-
tralizing antibodies. However, PEGylated Ads are also charac-
terized by reduced transduction efficacy due to the natural 
stealth effects of PEG, resulting in avoidance of the CAR-medi-
ated major uptake pathway. Therefore, redirection of PEGylated 
Ad technology by engineering specific affinities has been ex-
tensively explored and proposed as the second generation of 
Ad nanocomplexes (Fig. 2.1). The outer shell or distal end of 
PEG in Ad/polymer complexes has been conjugated with ac-
tive targeting moieties such as antibodies (22), growth factors 
(31, 33-39), small molecular complexes of peptides (arginine- 
glycine-aspartic acid; RGD), and ligands (27, 40) in order to di-
rect Ad to a targeted disease site (41). Direction of Ad com-
plexes via affinity tags results in accumulation of a high con-
centration of Ad nanocomplexes in tumor sites, leading to 
highly effective gene expression. 
Studies using PEGylated Ad have demonstrated reduced 
gene expression in CAR-expressing cells due to the masking of 
Ad capsid protein fiber by PEGylation. Studies by Eto et al. 
showed that administration of PEGylated Ad modified with 
RGD peptide motif results in 200-fold higher gene expression 
than unmodified PEGylated Ad, which lacks a targeting moiety 
(27). Specifically, this redirection of RGD on the surface of 
PEGylated Ad enhanced gene expression in both CAR-positive 
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and CAR-negative cells and indicated that redirection is neces-
sary for efficient infection by PEGylated Ad, which leads to an 
alternative pathway of cellular uptake. Various macromole-
cules, such as antibodies, have been conjugated to the end of 
PEG, as well as small molecules such as folic acid and peptide 
(27, 40, 42). Ogawara et al. reported that E-selectin antibody- 
conjugated Ad-PEG complexes are selectively targeted to tis-
sue inflamed by delayed type hypersensitivity reaction (36). In 
this study, systemic administration of E-selectin antibody-con-
jugated Ad-PEG complexes resulted in accumulation of Ad 
complexes in inflamed skin, resulting in local expression of 
the transgene luciferase. This study also showed that systemic 
administration of Ad tagged with antibodies, which can bind 
ligands specific to a disease site, can redirect Ad nanocom-
plexes to the desired target site. In addition, certain growth fac-
tors have been conjugated to the end of PEG in order to target 
specific receptors overexpressed in tumor tissue. Specifically, 
Park et al. published a study in which they conjugated epi-
dermal growth factor (EGF) to PEG, which targets epidermal 
growth factor receptor (EGFR) (37). EGFR is expressed in tu-
mors of epithelial origin and lung cancer and is involved in 
various signal cascades. Due to these characteristics, EGF has 
been employed as a ligand with nanoparticulate and diag-
nostic motifs. It was found that EGF tethered to the Ad surface 
resulted in highly efficient gene expression in A431 cells and 
MCF-7 cells expressing EGFR. These studies utilized a variety 
of small molecules and macromolecules as targeting moieties 
and showed that redirection to a target site was an effective ap-
proach for achieving high accumulation of Ad, leading to effi-
cient cellular uptake.
Charge conversion 
Mok et al. utilized new strategies to design Ad nanocomplexes 
with various surface charges by taking advantage of the unique 
pH microenvironment of tumors (43) (Fig. 2.3). The surface 
charges of Ad nanocomplexes in weakly acidic tumor micro-
environments can change from negative to positive upon 
cleavage of the citraconic amide linkage. This conversion to a 
positive charge increases contacts between the Ad complex 
surface and the negatively charged cellular membrane, leading 
to highly improved gene expression. The use of quantum dots 
as a fluorescence maker has resulted in increased cellular up-
take of charge-converted Ad nanocomplexes by direct tracking 
of Ad complexes. Tumor microenvironment-dependent 
charge-converted Ad nanocomplexes react only at the tumor 
site in a weakly acidic extra-tumoral environment ranging from 
pH 5.8 to pH 7.4. Therefore, self-modification of Ad nano-
complexes at disease sites is a valuable example that signifies 
the advanced design of Ad surface modifications.
Electrostatic interaction 
The surface charge of naked Ad is slightly negative at −4 mV, 
as measured by a zetapotentiometer (22). Based on this prop-
erty, Ad complexes were previously constructed using pos-
itively charged polymers, such as chitosan, poly-L-lysine, and 
arginine bioreducible polymer (ABP), via electrostatic interac-
tions (Fig. 2.2). One example of Ad nanocomplexes modified 
by electrostatic interaction is Ad complexed with PLL-PEG 
(44). The optimal structure of polymers that interact with Ad 
was investigated using block copolymers and grafting copoly-
mers while controlling the ratio of PLL and PEG. Ad/PLL-PEG 
complexes were treated with block and grafting PLL-PEG poly-
mers at three different grafting ratios (1：0.035, 1：0.084, and 
1：0.323). Gene expression in cells treated with PLL-PEG 
block copolymer showed 6-fold greater GFP expression than 
that induced by Ad treated with PLL-PEG grafting polymer at 
various ratios. These results indicate that polymer structure 
and optimal density of PEG may be critical factors for physical 
adsorption and eventually efficient celluar transduction. 
Therefore, Ad complexes formed through electrostatic inter-
action have the potential to enhance gene transduction in a 
non-specific manner.  
Bioreducible surface modification of Ad complexes 
An even more advanced design for Ad complexes has been 
demonstrated through complexation with arginine-grafted bio-
reducible polymer (ABP), which involves physical adsorption 
via electrostatic interactions onto the Ad surface (22, 47) (Fig. 
2). ABP has reducible disulfide bonds in its backbone and 
therefore is biodegraded under reducible conditions such as 
those found in the cytoplasm, which contains ~0.1-10 mM of 
the reducing molecule glutathione. These reducing conditions 
lead to the efficient release of Ad from polyplexes as well as a 
reduction in cytotoxicity. Enhanced transduction efficiency has 
been observed in cells treated with cationic ABP poly-
mer-coated Ad complexes compared to naked Ad. In addition, 
administration of ABP-coated Ad complexes produces higher 
levels of transgene expression than that of the cationic poly-
mer 25K PEI in cells expressing either high or low levels of 
CAR. These results confirm three major conclusions: (1) cati-
onic polymers can improve gene transfer efficiency of Ad to 
cells with variable CAR expression; (2) the transduction effi-
ciency of viral complexes formed with ABP is greater than that 
of complexes formed with 25K PEI cationic polymer; and (3) 
ABP promotes Ad transduction in both CAR-positive and 
CAR-negative cells by taking advantage of surface charge. 
Moreover, ABP-coated Ad complex induces a significantly 
weaker innate immune response relative to naked Ad, as as-
sessed by IL-6 cytokine release from macrophages. These stud-
ies indicate that gene expression and transduction efficacy of 
Ad complexes can be customized, depending on the function, 
properties, and design of the polymer used. Two effective ex-
amples are the engineering of Ad complexes modified based 
on electrostatic interaction and the bioreduction of the poly-
meric layer after administration.
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Ionic crosslinking of a chitosan layer processed by electro-
spinning
Another positive polymer utilized in engineering Ad complexes 
is PEGylated chitosan (Park et al., 2010). Notably, Ad com-
plexes after physical adsorption are stabilized by ionic cross- 
linking of tripolyphosphate, resulting in a firm polymeric layer. 
Furthermore, the formation of Ad complex with chitosan poly-
mers has been achieved by electrospinning, making steady 
production on a large scale possible. Ionic cross-linking of chi-
tosan formed a stable positively charged outer shell around the 
Ad and allowed for chemical conjugation to the numerous 
amine groups present (Fig. 2.5). Indeed, PEGylation via the 
amine groups of chitosan resulted in a weaker immune re-
sponse as well as increased plasma circulation half-life when 
compared to naked Ad. As a model tumor-targeting ligand, fol-
ic acid (FA) was also attached to the distal end of PEG and 
then conjugated to the amine groups of the chitosan layer, 
generating an Ad/chitosan-PEG-FA complex. The targeting abil-
ity of FA-conjugated Ad, with the amount of bound FA ligand 
carefully controlled, was measured using FA receptor-specific 
transduction. The results of this experiment showed that the 
transduction efficiency of PEG-conjugated Ad (Ad/chito-
san-PEG) was dramatically reduced compared to that of naked 
Ad in both FA receptor-positive and FA receptor-negative cells. 
This was due to physical blocking of the Ad capsid protein fi-
ber by PEG. In contrast, the level of GFP expression by Ad/chi-
tosan-PEG-FA was significantly increased compared to that in-
duced by naked Ad, specifically in FA receptor-positive KB 
cells but not in FA receptor-negative U343 cells. This result 
demonstrates that entry of FA receptor-targeted Ad/chito-
san-PEG-FA is dependent on the expression of the FA receptor 
on the cell surface. In addition, the transduction efficiency of 
Ad/chitosan-PEG-FA increased proportionally with the amount 
of surface-bound FA on Ad nanocomplexes, further supporting 
FA-mediated viral entry. Surprisingly, electrospinning did not 
impair the biological activity of Ad nor its ability to induce 
gene expression compared to that of naked Ad. These results 
indicate that Ad has considerable latitude, which can be ex-
ploited in engineering new Ad nanocomplexes. In summary, 
these results suggest that targeting of Ad is feasible by con-
jugating polymers along with an appropriate targeting moiety 
onto the Ad surface through electrospinning, thereby resulting 
in an effective method for the mass production of modified Ad 
nanocomplexes for clinical and animal studies.
ONCOLYTIC Ad WITH NANOCOMPLEXES FOR ANTICANCER 
THERAPEUTICS
Self-replicable oncolytic virus is recognized as a powerful ther-
apeutic tool that lyses cells, spreads, and then infects neighbor-
ing cancer cells. Along with efforts to develop Ad nano-
complexes, oncolytic Ad or replication competent Ad has also 
been modified with carrier materials (24, 26, 45, 46). Al-
though the advantage conferred by continuous infection of on-
colytic viruses potentially impacts virotherapy, naked onco-
lytic viruses have faced the same hurdles as non-replicating vi-
ruses, including issues related to inefficient systemic delivery.
Several groups have studied oncolytic Ads complexed with 
a polymer as a delivery carrier. Doronic et al. demonstrated 
that PEGylated oncolytic Ad causes reduced transduction of 
hepatocytes as well as hepatotoxicity after systemic admin-
istration, resulting in a higher survival rate compared to naked 
oncolytic Ad (26). Visual evidence of biodistribution was 
made possible by the bioluminescence of luciferase-expressing 
Ad. These experiments showed that the intensity of bio-
luminescence was reduced 19-90 times in the liver compared 
to unmodified naked oncolytic Ad. However, the transduction 
level in cells treated with PEGylated Ad was not significantly 
different at the tumor site compared to that of naked oncolytic 
Ad. Although PEGylated oncolytic Ad improved the plasma 
circulation half-life and reduced biodistribution in undesired 
organs, the fact that Ad complexes lacked specificity to target 
tumor cells resulted in a comparable transduction level via the 
passive EPR effect. 
Critical differences in transduction levels at the target tumor 
site were achieved by Her2/neu-targeted and PEGylated onco-
lytic Ad, which has a Herceptin Ab at the distal end of PEG 
(48). Relaxin-expressing oncolytic Ad (DWP418) was chemi-
cally conjugated with PEG. Her2/neu-specific Herceptin anti-
body was then conjugated to the end of biheterofunctional 
PEG for Her2/neu-targeted cancer gene therapy. DWP418- 
PEG-HER had Her2/neu-dependent oncolytic activity, indicat-
ing that the Herceptin-targeting moiety directed selective entry 
of this Ad nanocomplex into Her2/neu-positive cells. DWP418- 
PEG-HER elicited greater anti-tumor activity in vivo towards 
Her2/neu-positive SK-OV3 and MDA-MB435 xenograft tumors 
than did either naked DWP418 or DWP418-PEG. In contrast, 
DWP418-PEG-HER had equivalent anti-tumor activity as DWP 
418-PEG against Her2/neu-negative MCF7-mot tumors. Thus, 
the enhanced anti-tumor activity of DWP418-PEG-HER in 
Her2/neu-positive tumors is based upon targeting of the Ad 
nanocomplex to the tumor through specific interaction be-
tween Herceptin and Her2/neu on the cell surface. Moreover, 
quantitative PCR assay also resulted in a significant increase in 
highly localized DWP418-PEG-HER in tumor cells. This in-
crease was as much as 5.8 × 104-fold higher compared to that 
produced by naked DWP418. In addition, there was a 3.7 × 
105-fold reduction in the biodistribution of Ad in the liver 
when DWP418-PEG-HER was administered compared to nak-
ed Ad. Thus, the increase in tumor-to-liver ratio was 1010-fold 
for DWP418-PEG-HER versus naked Ad. This result critically 
shows that affinity tags enable highly-specific tumor targeting, 
resulting in enhanced accumulation of Ad in tumor tissue. 
Furthermore, successive secondary replication of oncolytic Ad 
amplifies the high local concentration of therapeutic Ad in tu-
mor tissue, resulting in high anti-tumor activity. No apparent 
toxicity was noted in animals that received DWP418-PEG or 
DWP418-PEG-HER during the course of this study. Ad-related 
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liver toxicity, as measured by serum ALT and AST levels, was 
absent in PEGylated Ad-treated animals. Taken together, these 
results demonstrate the potential for effective and safe systemic 
therapies for the treatment of both primary and metastatic 
tumors.
FUTURE DIRECTIONS
The first generation of Ad nanocomplexes was modified using 
simple PEGylation or a variety of polymers such as pHPMA, 
PLL, and ABP in order to prolong circulation time, reduce tox-
icity, and enhance the EPR effect. With the development of di-
verse carrier designs and materials, Ad nanocomplexes have 
evolved into potent cancer therapeutics tools (48), gene deliv-
ery systems (2), and imaging agents (17, 49). The therapeutic 
effects of these versatile novel Ad nanocomplexes should be 
characterized in vivo in order to validate their practical poten-
tial in a clinical setting. Exploitation of the new generation of 
Ad nanocomplexes may greatly impact the fields of cancer 
gene therapy, virotherapy, and therapeutic diagnostics. 
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